Every GxP discipline

Understand Find the gaps before FDA does.

A free library for everyone in life sciences, and a workspace for quality teams and the consultants who support them.

01 · ScopeWhat are we checking?Halden Pharmaceuticals’ drug manufacturing, against FDA’s own program.
02 · CoverageWhat would FDA look at?Six quality systems. Quality is always one of them.
03 · EvidenceWhat do the records show?Three records pulled for the Quality system.
04 · FindingWhere is the gap?An investigation that stopped at one lot. 21 CFR 211.192.
05 · ReviewDoes it hold up?The finding is checked against its evidence before anything goes out.
06 · ReportWhat needs fixing?Report R-5304-F497 lists each gap and its fix. Anyone can verify its ID.
The SPEQ Library · free

Everything GxP, free to read.

Standards, topics, how-to guides, tools, templates and drug approvals for everyone in life sciences. No account needed to read.

A page from the Library21 CFR 211.192

Investigations of discrepancies and failures

What it means

A batch or component failed to meet specification, or an unexplained discrepancy occurred, and the firm either did not investigate, investigated inadequately, or did not extend the investigation to other batches and products that could have been affected.

How to comply
  • Extend the investigation to other batches and other products that may have been associated with the same failure, and document that scope decision.
  • Drive the conclusion into CAPA so the root cause is corrected, not just the batch dispositioned.
Read the full page

The SPEQ Library

Listen: what the Library is for

0:00 / 0:31

Loading the audio…

Read the transcript

WHAT THE SPEQ LIBRARY IS FOR

The SPEQ Library is free, for everyone in life sciences. It explains GxP in plain language: what the regulations require, what FDA actually cites, and how the work gets done. You’ll find standards, topics, step-by-step guides, templates and tools, with no account needed to read them. Whether you’re new to quality or preparing for an inspection, start with what you need today. And when you’re ready to find the gaps in your own quality system before FDA does, the SPEQ workspace is built on the same foundation.

Narrated with a synthetic voice. The transcript is the exact narration script.

What is at stake

An inspection is too late to find out.

A gap FDA finds first can mean a Form FDA 483, a warning letter, or an approval that waits. A gap you find first is a fix on your own schedule.

What FDA has on record

FDA’s public inspection record, searchable in SPEQ. See what FDA cites in the areas you are responsible for:

  • 355,000+inspections
  • 140,000+citations
  • 2,300+warning letters

SPEQ’s own FDA record, counted 19 November 2026.

What better quality can return

FDA says even incremental investments in quality management can yield returns. In one example it cites, a biopharma site reported:

  • 50%+fewer product defects
  • 75%less waste
  • 25%of staff redirected to other work

FDA Office of Pharmaceutical Quality, July 2025, citing McKinsey, 2017.

One assessment, start to finish

It starts with FDA’s method. It ends with gaps you can fix.

Follow one assessment at Halden Pharmaceuticals through six steps. Every finding names the gap, the regulation and the page that proves it.

Engagement · Halden Pharmaceuticals, Site 2Scope

Inspection readiness assessment for drug product manufacturing.

Stage: commercial manufacturingProgram: CP 7356.002Method: IOM Chapter 5
Coverage · CP 7356.002
  • QualityIn scope · 1 open
  • Facilities and equipmentOut
  • MaterialsIn scope
  • ProductionIn scope
  • Packaging and labelingOut
  • Laboratory controlIn scope

Full inspection. Quality is always in scope; four systems are covered.

Evidence · Quality system3 exhibits
  • E-04INV-24-118 OOS investigation
  • E-05Batch records lots 24-117 and 24-119
  • E-06Interview note, QA manager
FND-001 · MajorQuality system

The OOS investigation for lot 24-118 did not extend to other lots of the same product, so the discrepancy is not shown to be contained.

21 CFR 211.192E-04E-05ApprovedIn review
Report · your letterhead · Report ID on every page
Northgate Quality Partners
Assessment report for Halden Pharmaceuticals
Issue 1 · issued 2026-10-30
Confidential to client
Engagement · Halden Pharmaceuticals, Site 2Scope

Inspection readiness assessment for drug product manufacturing.

Stage: commercial manufacturingProgram: CP 7356.002Method: IOM Chapter 5
Coverage · CP 7356.002
  • Quality1 finding
  • Facilities and equipmentOut
  • MaterialsCovered
  • ProductionCovered
  • Packaging and labelingOut
  • Laboratory controlCovered
Evidence · Quality system3 exhibits
  • E-04INV-24-118 OOS investigation
  • E-05Batch records lots 24-117 and 24-119
  • E-06Interview note, QA manager
FND-001 · MajorQuality system

The OOS investigation for lot 24-118 did not extend to other lots of the same product, so the discrepancy is not shown to be contained.

21 CFR 211.192E-04E-05ApprovedIn review
R-5304-F497Report ID, on every page.
Anyone can verify it, no account needed.
Prepared with SPEQ

Step 1 of 6
See the output

Read a sample report.

One full assessment report for a fictional firm, from what to fix first to the evidence behind each finding.

  • ConsultantsYour name on the report.
  • Quality teamsKnow before FDA arrives.
Free for every practitioner

How mature is your quality system?

Take the free maturity assessment across 12 domains, with a read on FDA’s Quality Management Maturity practice areas. Create a free account to keep your results and build on them.

SPEQ’s own assessment. It is not an FDA rating.

  • Your maturity resultsYour score, your history and your emailed report
  • Saved standards and notesKeep what you need, with your own notes
  • A watchlistFollow up to 25 records
  • Tools and templatesThe free ones, plus a monthly allowance of more
  • Your learning progressPick up where you left off
Proof and trust

Anyone can confirm a report is genuine.

Every issued report carries a Report ID. Enter it to see who issued it, when, and whether a later issue replaced it. No account needed.

  • Your records stay yours.Each practice’s records are kept apart by rules in the database.
  • Clients never sign in.They receive the report, and nothing else.

No account needed. Enter the ID from the footer of any issued report, or the full fingerprint from its cover. Open the live check

Issued, and the current issue

Issued by
Northgate Quality Partners
Issue
Issue 1, issued 2026-10-30
Report ID
R-5304-F497
Fingerprint
5304f4971485331a9cc14d8ecd1726c2efc11a2bfba6cf8b22e6204a96150c4b

This is a synthetic demonstration record, not a client engagement.

Then check your fileChoose the PDF you were sent. It is compared, in your browser, with the files that were issued. Check a file

No issued report matches that ID

Check it against the footer of the report. If it still does not match, ask the practice that sent it.

One workspace, priced for the practice.

A plan for a practice of one and a plan for a firm. The library stays free either way.

See pricing
Questions

What people ask first.

Is SPEQ endorsed by FDA?

No. SPEQ is independent. It follows FDA’s published compliance programs and Investigations Operations Manual, and FDA has no part in it.

Does FDA see my report?

No. SPEQ doesn’t send anything to FDA. The report is for you or your client, so the gaps can be fixed.

Is the maturity score an FDA rating?

No. It is SPEQ’s own assessment. FDA’s Quality Management Maturity program is separate and run by FDA.

Is client data used to train AI?

No.

What is free?

The Library, its search, a free account, and the maturity assessment. You don’t need a card.

Who is it for?

Quality and regulatory teams, the consultants who support them, and anyone learning GxP work.

Start

Find the gaps before FDA does.

Your first assessment starts with what you need to know. It ends with a report that shows what to fix.